Clinical data | |
---|---|
Other names | Testosterone 17β-benzoate; Androst-4-en-17β-ol-3-one 17β-benzoate |
Routes of administration | Intramuscular injection |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.016.575 |
Chemical and physical data | |
Formula | C26H32O3 |
Molar mass | 392.539 g·mol−1 |
3D model (JSmol) | |
| |
|
Testosterone benzoate, or testosterone 17β-benzoate, also known as androst-4-en-17β-ol-3-one 17β-benzoate, is a synthetic, injected anabolic–androgenic steroid (AAS) and an androgen ester – specifically, the benzoate C17β ester of testosterone – which was never marketed.[1][2] It is a prodrug of testosterone and, when administered via intramuscular injection, is associated with a long-lasting depot effect and extended duration of action.[3][4][5] The drug was first described in 1936 and was the first androgen ester and ester of testosterone to be synthesized.[6]